An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER Study) The primary objective of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer The primary objective of the Phase I part of this study is: · To establish the appropriate doses of paclitaxel and AZD2281 in combination, based on safety and tolerability (for use in the randomised P...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60 mg AZD9668 Administered Orally Twice Daily to Subjects with Chronic Obstructive Pulmonary Disease (COPD) on Treatment with budesonide/formoterol To evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD subjects by assessing effect on lung function and symptoms of COPD.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin compared with Placebo in Adult Patients with Type 2 Diabetes and Renal Impairment (Moderate, Severe, and End-Stage) with an additional 40-week, Randomized, Parallel-group, Double-blind, Placebo-controlled Long-term Observational Period Short-term: To evaluate the efficacy of saxagliptin 2.5 mg in adult patients with type 2 diabetes and renal impairment (moderate, severe and end-stage) compared with placebo by assessment of the absol...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC) To determine the efficacy of cediranib when added to cisplatin plus a fluoropyrimidine compared to cisplatin plus a fluoropyrimidine alone by assessment of overall survival (OS).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude D5160C00035 : étude de phase 1 visant à évaluer la pharmacocinétique, la sécurité d’emploi et la tolérance de l’osimertinib chez des patients ayant des tumeurs solides avancées et avec une fonction rénale normale ou une insuffisance rénale sévère. [essai clos aux inclusions] Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquents puisque, à eux seuls, ils représentent 90% des cancers humains. L’o...

• Pays France
• Organes Tumeurs solides
• Spécialités Thérapies Ciblées

A Phase III Study of MEDI4736 versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio de fase III de MEDI4736 frente al tratamiento estándar en pacientes con carcinoma pulmonar no microcítico localmente avanzado To assess the efficacy of MEDI4736 treatment compared with Standard of Care in terms of Overall survival (OS) and Progression free survival (PFS). Evaluar la eficacia del tratamiento con MEDI473...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude NIAGARA : étude de phase 3, randomisée, en ouvert, visant à déterminer l'efficacité et la tolérance d'un traitement associant le durvalumab et une chimiothérapie par gemcitabine et cisplatine comme traitement néoadjuvant, suivi par du durvalumab seul comme traitement adjuvant, chez des patients ayant un cancer de la vessie sans envahissement musculaire. A phase III, randomized, open-label, multi-center, global study to determine the efficacy and safety of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durva...

• Pays France
• Organes Vessie
• Spécialités Immunothérapie - Vaccinothérapie, Chimiothérapie

RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study The primary objective for the study is to evaluate the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme (300 mg on day 1, 600 mg on day 2 and 800 mg on day 3) ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg when given as Neoadjuvant Treatment in Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0) To compare the effects of fulvestrant 500 mg and fulvestrant 250 mg on the proliferation marker Ki67 at 4 weeks

• Pays Aucun
• Organes Aucun
• Spécialités Aucune